Skip to content

Anna-Maria Langkilde

University Medical Center Groningen

3 papers in the Anchorcite directory, published between 2018 and 2020, cited 20,121 times in total.

Research topics

Frequent co-authors

Papers

  1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations

    BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…

  2. Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine · 2018 · 6,600 citations

    BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes)…

  3. Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine · 2020 · 5,992 citations

    BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known. METHODS: of body-surface area and…

Metadata from OpenAlex (CC0).